- Fusion Pharmaceuticals Inc FUSN has announced preliminary Phase 1 data from the single-dose portion of the study evaluating FPI-1434 in patients with IGF-1R expressing solid tumors.
- Data were shared at the Society of Nuclear Medicine and Molecular Imaging Virtual Annual Meeting.
- Results from the first three patient cohorts (n=12) demonstrated a favorable safety profile for FPI-1434.
- No drug-related serious adverse events or dose-limiting toxicity were reported in administered activity up to 40 kBq/kg body weight, and dosimetric results were within normal organ radiation tolerability limits. The single dose-escalation portion of the study has concluded while enrollment into the multi-dosing cohorts is ongoing.
- Separately, Fusion presented preclinical data demonstrating synergistic efficacy against olaparib-resistant colorectal and radioresistant lung cancer xenografts when combining FPI-1434 with AstraZeneca Plc's AZN - Merck & Co Inc's MRK Lynparza (olaparib).
- Combining the two therapeutics resulted in anti-tumor efficacy against colorectal and non-small cell lung cancer tumor models.
- The strongest combination effect was observed at the lowest single-agent doses.
- Fusion also presented preclinical data showing that treatment with FPI-1434 combined with immune checkpoint inhibitors resulted in complete tumor eradication.
- FPI-1434 is a radioimmunoconjugate designed to target and deliver alpha emitting medical isotopes to cancer cells expressing IGF-1R, a receptor that is overexpressed on many tumor types.
- Price Action: FUSN shares are up 8.33% at $8.84 during the premarket session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
